// App-Quantinova.ai

e21106 : C-reactive protein (CRP) as a predictive marker for survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first line pembrolizumab monotherapy.

Researchers

Presenter

  • Yuji Shibata

Principal Investigators

  • Tadasuke Shimokawaji

  • Tetsuro Kondo

  • Terufumi Kato

  • Haruhiro Saito

  • Kouzo Yamada

Medical Centers

  • Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • C reactive protein

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved